AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer
Question
AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer
Direct answer
AstraZeneca and partner HUTCHMED formally submitted an NDA to the US FDA for the savolitinib plus osimertinib combination regimen. The therapy addresses patients with MET-driven non-small cell lung cancer who developed resistance to initial targeted treatments. An approval would extend Tagrisso's product lifecycle and establish savolitinib's first commercial entry into the US oncology market, triggering commercial milestone schedules. — bullish pressure on AZN.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-29
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer”, revision 1, evidence through 2026-09-29. https://marketontology.com/catalysts/2026-09-29/astrazeneca-files-us-fda-nda-for-savolitinib-combo-in-met-driven-lung-cancer-9e2a9f
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| AZN | ▲Bull | 1–3 months | Policy Shift | 73 |
AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer
AstraZeneca and partner HUTCHMED formally submitted an NDA to the US FDA for the savolitinib plus osimertinib combination regimen. The therapy addresses patients with MET-driven non-small cell lung cancer who developed resistance to initial targeted treatments. An approval would extend Tagrisso's product lifecycle and establish savolitinib's first commercial entry into the US oncology market, triggering commercial milestone schedules. — bullish pressure on AZN.
AstraZeneca and partner HUTCHMED formally submitted an NDA to the US FDA for the savolitinib plus osimertinib combination regimen. The therapy addresses patients with MET-driven non-small cell lung cancer who developed resistance to initial targeted treatments. An approval would extend Tagrisso's product lifecycle and establish savolitinib's first commercial entry into the US oncology market, triggering commercial milestone schedules.
- SummaryAstraZeneca and partner HUTCHMED formally submitted an NDA to the US FDA for the savolitinib plus osimertinib combination regimen. The therapy addresses patients with MET-driven non-small cell lung cancer who developed resistance to initial targeted treatments. An approval would extend Tagrisso's product lifecycle and establish savolitinib's first commercial entry into the US oncology market, triggering commercial milestone schedules.
- AZNDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- AZN closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- AZN price vs. pre-event level
- AZN volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-24Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 CongressAZN HCM+4.82%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.